Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VERA vs MLTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MLTX Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 3–3 Matrix Metrics)

MLTX Overall Winner 6-Pillar Tally: VERA 1 – 3 MLTX (2 Tie) Matrix Metrics: VERA 3 – 3 MLTX

As of Nov 16, 2026, MoonLake Immunotherapeutics Class A (MLTX) is the stronger overall head-to-head candidate over Vera Therapeutics, Inc. (VERA) in the Tradestie Institutional Equity Comparison Engine, winning 3–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). VERA carries a Unified Composite Score of 45.9/100 (HOLD) at $27.26 (N/M Forward P/E, -4160.1% operating margin), whereas MLTX carries 38.3/100 (SELL) at $11.85 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While VERA currently prints a higher short-term Unified Composite Score (45.9/100 HOLD vs. MLTX 38.3/100 SELL), MLTX captures the overall institutional head-to-head verdict (3–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -4160.1% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: VERA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.7); meanwhile MLTX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VERA vs MLTX
VERA NASDAQ
Vera Therapeutics, Inc. Class A Common Stock
Pharmaceutical Preparations
$27.26
-2.99% 1D
Market Cap $2.1B
TTM Revenue $10M
Forward P/E N/M
Beta / 30D Vol 1.12β · 57% Vol
Unified Composite Score
45.9 / 100 HOLD
Tech 32.0 Fund 51.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.0%), weak momentum, RSI 39
RSI-14: 38.7 · SMA20: $29.87 · SMA50: $30.93
MLTX NASDAQ Head-to-Head Winner
MoonLake Immunotherapeutics Class A Ordinary Shares
Pharmaceutical Preparations
$11.85
-5.2% 1D
Market Cap $1.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.61β · 90% Vol
Unified Composite Score
38.3 / 100 SELL
Tech 32.0 Fund 44.0 Flow 75.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -11.8%) with fading momentum, RSI 50
RSI-14: 49.5 · SMA20: $11.93 · SMA50: $11.82

6-Pillar Scorecard Institutional Category Breakdown (VERA 1 – 3 MLTX)

Columns: Metric · VERA · MLTX
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale VERA
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $10M N/A
Market Cap $2.1B $1.1B
3. Profitability & Quality MLTX
Gross Margin 67.9% N/A
Operating Margin -4160.1% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -113.5% -81.5%
4. Balance Sheet & Cash Flow MLTX
Cash Generation (TTM) -$377M -$244M
Cash Flow Margin N/A N/A
Net Cash / Leverage $21M Net Debt (0.23x D/E) $278M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MLTX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 108.9% (68th %ile) 111.8% (7th %ile)
Put/Call OI Skew 0.02x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown ACCUMULATION · Distribution
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VERA (3) vs MLTX (3)
Institutional Metric VERA MLTX Criterion Row Edge
Market Capitalization
Scale
$2.1B $1.1B Larger Scale VERA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
-4160.1% 0.0% Higher Margin MLTX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-113.5% -81.5% Higher ROE MLTX
52-Week Range Position
Momentum
3% ($26–$56) 17% ($9–$23) Stronger Trend MLTX
Beta / 30D Volatility
Risk Regime
1.12β · 57% Vol 1.61β · 90% Vol Lower Realized Risk VERA
Unified Institutional Score
Composite Signal
45.9 / 100 (HOLD) 38.3 / 100 (SELL) Higher Composite VERA
Trailing 12M Revenue (USD)
Operating Scale
$10M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
67.9% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$377M ($21M Net Debt (0.23x D/E)) -$244M ($278M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MLTX +26.3 pp
VERA: -2.22% · MLTX: +24.08%
3M Horizon VERA +11.93 pp
VERA: -15.55% · MLTX: -27.48%
6M Horizon VERA +7.28 pp
VERA: -20.64% · MLTX: -27.92%
1Y Horizon VERA +1.74 pp
VERA: -3.91% · MLTX: -5.65%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VERA vs MLTX. Trailing 12-month operating profitability (VERA -4160.1% vs MLTX 0.0%) and valuation multiples (VERA N/M vs MLTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

VERA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$10M
Gross Margin67.9%
Op. Margin-4160.1%
ROE / Fwd P/E-113.5% · N/M
MLTX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-81.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VERA BREAKDOWN
98d in phase · OBV DISTRIBUTION
Current IV 108.9%
IV Percentile 68th %ile
Put/Call OI Skew 0.02x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact VERA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MLTX BREAKDOWN
103d in phase · OBV ACCUMULATION
Current IV 111.8%
IV Percentile 7th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact MLTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VERA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.1B market capitalization and -4160.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MLTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VERA vs MLTX Key Questions & Quantitative Answers

As of Nov 16, 2026, MoonLake Immunotherapeutics Class A (MLTX) is the stronger overall head-to-head candidate over Vera Therapeutics, Inc. (VERA) in the Tradestie Institutional Equity Comparison Engine, winning 3–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). VERA carries a Unified Composite Score of 45.9/100 (HOLD) at $27.26 (N/M Forward P/E, -4160.1% operating margin), whereas MLTX carries 38.3/100 (SELL) at $11.85 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While VERA currently prints a higher short-term Unified Composite Score (45.9/100 HOLD vs. MLTX 38.3/100 SELL), MLTX captures the overall institutional head-to-head verdict (3–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -4160.1% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: VERA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.7); meanwhile MLTX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 49.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VERA leads the Growth & Scale pillar: VERA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $10M TTM revenue (67.9% gross margin, -4160.1% operating margin), compared with MLTX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, VERA generates $10M in USD-normalized revenue versus N/A for MLTX. In operating R&D and SG&A reinvestment, VERA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MLTX.

VERA and MLTX trade at balanced relative valuation multiples. VERA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas MLTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VERA (-113.5% ROE) versus MLTX (-81.5% ROE) capital efficiency.

In options market volatility and institutional positioning, VERA carries 108.9% implied volatility (68th %ile, Elevated (60th–80th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.12β · 57% Vol realized risk). By comparison, MLTX carries 111.8% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.61β · 90% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.